Laser/drug treatment for AMD (advanced micro devices) lasts two years:
This article was originally published in Clinica
Initial results from a Phase III trial of Visudyne phototherapy for treating age-related macular degeneration (AMD) have shown that its benefits are sustained over a two-year period. The treatment, in which the drug is injected into the arm and non-thermal laser light is shined on the eye, is under development by CIBA Vision and Vancouver, Canada-based QLT PhotoTherapeutics. It is in a Phase III trial for wet AMD and a Phase IIIb trial for choroidal neovascularisation.
You may also be interested in...
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.